Alzheimer’s disease as oligomeropathy
Abstract
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder and is characterized by pathological aggregates of amyloid β-protein (Aβ) and tau protein. On the basis of genetic evidence, biochemical data, and animal models, Aβ has been suggested to be responsible for the pathogenesis of AD (the amyloid hypothesis). Aβ molecules tend to aggregate to form oligomers, protofibrils, and mature fibrils. Although mature fibrils in the final stage have been thought to be the cause of AD pathogenesis, recent studies using synthetic Aβ peptides, a cell culture model, Aβ precursor protein transgenic mice models, and human samples, such as cerebrospinal fluids and postmortem brains of AD patients, suggest that pre-fibrillar forms (oligomers of Aβ) are more deleterious than are extracellular fibril forms. Based on this recent evidence showing that oligomers have a central role in the pathogenesis of AD, the term "oligomeropathy" could be used to define AD and other protein-misfolding diseases. In this review, I discuss recent developments in the "oligomer hypothesis" including our research findings regarding the pathogenesis of AD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Oligomeric Aβ peptides are more destructive than Aβ monomers and fibrillar forms in the brain.
“it has been observed that oligomeric Aβ peptides are more destructive than Aβ monomers and fibrillar forms in the brain [132,133].”
From Beneficial Effects of Spirulina Consumption on Brain Health (2022) · cites this paper as [132]
The citation lists haven’t been fetched yet
References 173 · Cited by 129
- Authors
- Ono, K.
- Affiliations
- SHOWA Medical University (JP)
- Corresponding author
- Ono, Kenjiro
- ORCID
- Ono, Kenjiro
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 119
- Pages
- 57-70
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W2750472319
- Cited by
- 129
- References
- 173
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 14 · 2023: 13 · 2022: 17 · 2021: 18 · 2020: 19 · 2019: 13 · 2018: 8 · 2017: 3
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurochemistry International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Grant-in-Aid for Young Scientists (22790815)
- Scientific Research (26461266)
- Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan
- Japan Health Sciences Foundation
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Novartis Foundation for Gerontological Research
- Department of Medicine at Showa University
- Takeda Science Foundation
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, amyloid oligomers, amyloid hypothesis, protein misfolding, tau protein, amyloid fibrils, neurodegeneration, pathogenesis
- MeSH terms
- Alzheimer Disease, Animals, Brain, Disease Models, Animal, Humans, Peptide Fragments, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review